CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2014—NanoString Technologies launched its nCounter Dx Analysis System for high-complexity, CLIA-certified laboratories. The nCounter Dx Analysis System is the only platform 510(k) cleared by the FDA to run the Prosigna Prognostic Breast Cancer Gene Signature Assay.
The FLEX configuration offered on the nCounter system supports other translational research applications and facilitates the ability of laboratories to develop their own assays. The nCounter Elements General Purpose Reagents provide further flexibility by enabling laboratories to develop their own gene expression, copy number variation, and gene fusion signatures.
NanoString showcased the nCounter Dx Analysis System and its advanced capabilities at the annual Association for Molecular Pathology conference in November. The system is available for purchase or through rental arrangements in the U.S. and countries that accept the CE mark.
NanoString Technologies, 888-358-6266